

Table S1. Effect of anti-DV1 serum and viral dose on morbidity and mortality.

Serum ^a	DV2 dose (pfu)	Morbidity ^b	Morbidity p-value vs. NMS control ^c	Mortality	Mean survival time \pm s.d. (days) ^d	Mortality p-value vs. NMS control ^e
NMS ^f	10 ⁷	15/15		14/15	4.2 \pm 0.4	
NMS	10 ⁶	6/7		0/7	n.a. ^g	
α -DV1 ^h	10 ⁶	12/12	0.5	11/12	3.5 \pm 0.3	0.003
NMS	10 ⁵	0/11		0/11	n.a.	
α -DV1	10 ⁵	4/4	0.03	4/4	4.0 \pm 0.0	0.001
NMS	10 ⁴	0/4		0/4	n.a.	
α -DV1	10 ⁴	4/4	0.03	1/4	5.5	0.3

^a100 μ l of the indicated antiserum was given to all mice in each group.

^bMice were scored as morbid if hunched posture, ruffled fur, and lethargy were simultaneously present at any time during the first ten days post-infection.

^cResult of two-sided Fisher's exact test comparing α -DV1 recipients to NMS recipients at the same viral dose.

^dMean survival time of mice who succumbed to infection during 10-day timecourse.

^eResult of logrank analysis comparing anti-DV1 recipients to NMS recipients at the same viral dose.

^fNaive mouse serum.

^gNot applicable. No mortality occurred in these groups.

^hAnti-DV1 serum collected 8 weeks after infection of AG129 mice with 10⁵ pfu DV1.